

Redaktionell annons i The Pathologist

Lumito annonserar i The Pathologist för att öka kännedomen och intresset för produktlösningen Scizys by Lumito bland patologer och forskare. Den redaktionella annonsen finns med i decembermånads digitala utgåva och du kan läsa den [här](#).

Annonsen finns även publicerad på Lumitos [hemsida](#).



Sponsored Feature

Digital Imaging - Upgraded

How Lumito's innovative labeling system offers fresh insights into tissue diagnostics

The team at Lumito is passionate about presenting an innovative new digital imaging technology. The ultimate driving ambition? To offer powerful tools that meet rapid, safe tissue diagnostics requirements. More specifically, Lumito wants to provide pathologists and researchers with images that form a more comprehensive, histology-based foundation for their analyses and clinical diagnostics. Andreas Johansson, CTO at Lumito, says the company is currently working hard on finalizing its first product for researchers – SCIZYS by Lumito. The plan is to launch during the first part of 2023. This WSI scanner, combined with Lumito's upconverted nanoparticle (UCNP) reagents, provides high-quality immunohistochemistry (IHC) imaging with unique qualities. The SCIZYS offering also enables imaging of tissue traditionally stained with hematoxylin in addition to the UCNP imaging modality.

Better technology means better results. Lumito's technology enables image capture with higher contrast, increased dynamic range, and reduced nonspecific binding. Through higher analysis quality and shorter analysis time, tissue diagnostics can achieve significant improvements. "It is possible to switch between visualizing the morphology of our unique UCNP IHC labeling. The system's flexibility also allows visualization of both readings simultaneously, superimposed on the same image. This will provide more detailed information, but without the issues with overlap that traditional IHC technology provides," says Johansson. Lumito has recently completed a successful preliminary study with Umeå University under the leadership of assistant university lecturer Daniel Öhlund (1). The research group has mapped how the company's UCNP technology can improve our ability to visualize protein expression in pancreatic cancer. Lumito's imaging technology has provided additional insight by illustrating how specific proteins are secreted by cancer cells and penetrate the tumor stroma, Öhlund reports. But that's just one study; Lumito has several others underway. For example, a proof-of-concept study is currently exploring the potential of Lumito's UCNP to detect immune complexes and complement deposits in renal biopsies – a collaboration between University Hospitals Coventry and Warwickshire NHS Trust in the UK and a research team led by Kishore Gopalakrishnan. "With Lumito's technique, we hope the problem of background staining can be eliminated by clearer imaging of renal biopsy tissue," says Gopalakrishnan. There will also be the added advantage of being able to preserve the slides for review. In addition, being able to use formalin-fixed, paraffin-embedded tissue would potentially mean an additional biopsy core of fresh tissue will not be required!"

If you're excited about the technology's potential, Johansson has an invitation, "We are always interested in getting in touch with more research groups to map out where our product brings the most value."

www.lumito.se/en
For research use only.

Reference

1. T. Lickström et al., "Extracellular galectin-4 drives immune evasion and promotes T-cell apoptosis in pancreatic cancer" [submitted] (2022).

LUMITO

www.lumito.se/en

Vi har valt att annonsera i The Pathologist eftersom vi då har möjlighet att nå totalt 200 000 yrkesverksamma inom laboratoriebranschen, Professionella som specialiserat sig på anatomisk patologi, klinisk patologi, digital patologi, på akademiska och kliniska laboratorier, forskningslaboratorier och sjukhus samt 75 000 läsare av den digitala versionen av The Pathologist varje månad. Vi når allt från blivande patologer till erfarna laboratoriechefer och avdelningschefer.

För ytterligare information, vänligen kontakta:

Lumitos VD, Mattias Lundin
e-post: ml@lumito.se
tel: 076-868 45 09

www.lumito.se

Lumito är specialiserat inom medicinsk teknik för digital patologi. Genom sin egenutvecklade och patenterade teknik vill Lumito ge vårdgivarna ett kraftfullt verktyg för att möta kraven på snabb och säker vävnadsdiagnostik i den individanpassade sjukvården. Tekniken möjliggör bilder med större kontrast där oväsentlig bakgrundsinformation sorteras bort, vilket gör det lättare för patologer och forskare att finna cancerindikationer. Tekniken som baseras på uppkonverterande nanopartiklar (UCNP - Up Converting Nano Particles) har förutsättningar att väsentligt förbättra diagnostiken av vävnadsprover genom högre kvalitet av analyserna och kortare analysstider. Metoden har flera potentiella användningsområden, men i första hand har Lumito valt att fokusera på digital patologi och först på en lansering av SCIZYS by Lumito för forskningslaboratorier. Bolaget är en spinoff från en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. www.lumito.se.

Aktien handlas på NGM Nordic SME, under namnet LUMITO och Mentor är Mangold Fondkommission, telefon: 08-503 015 50.